Stratification of Venous Thromboembolism Risk in Ovarian Cancer Patients During Chemotherapy
International Journal of Gynecological Cancer, ISSN: 1048-891X, Vol: 19, Issue: 1, Page: 79-83
2009
- 15Citations
- 20Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- CrossRef15
- 15
- Captures20
- Readers20
- 20
Article Description
The prevalence of venous thromboembolism (VTE) in ovarian cancer during first-line chemotherapy (CHT) ranges between 6.4% and 10.6%. Identification of the susceptible population is crucial for effective thromboprophylaxis. We performed a retrospective study of all our patients with epithelial ovarian cancer who underwent ambulatory first-line CHT between 1990 and 2004. Data were collected regarding age, body mass index (BMI), previous deep vein thrombosis, pulmonary embolism (PE), menopause status, FIGO stage, grade, histology, type of surgery, residual disease, and CHT. Univariable and multivariable regression analyses were performed to assess independent prognostic factors for VTE/PE to calculate a prognostic index (PI). Of 203 patients, 16 (7.8%) had symptomatic VTE: 15 deep vein thrombosis and 1 PE. Multivariable regression analysis found that age ( P = 0.01), BMI ( P = 0.01), and stage ( P = 0.05) were independent prognostic factors for VTE. Age, BMI, and stage were used to calculate the PI: 0.285 × age + 0.555 × BMI + 1.110 × stage. The PI was dichotomized according to its median cutoff (5.8) to define a low (3.8% at 6 months) and a high (11.3%) VTE incidence group. Age, BMI, and stage permit to identify ovarian cancer patients with a high risk in developing symptomatic VTE during CHT.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1048891X24026604; http://dx.doi.org/10.1111/igj.0b013e318199035e; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=65649110455&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19258946; https://linkinghub.elsevier.com/retrieve/pii/S1048891X24026604; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00009577-200901000-00015; http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2FIGJ.0b013e318199035e; https://dx.doi.org/10.1111/igj.0b013e318199035e; https://ijgc.bmj.com/content/19/1/79
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know